VE 3539
Alternative Names: VE-3539Latest Information Update: 28 Aug 2023
At a glance
- Originator Verseon
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic retinopathy
- No development reported Diabetic macular oedema
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (PO)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Diabetic-macular-oedema(Prevention) in USA (PO)
- 05 Aug 2021 Preclinical trials is still ongoing for Diabetic macular oedema in USA